Scius Communications is focused on providing strategic communications to life science companies at all stages of development to support the achievement of your corporate objectives, whether they be partnering or financing. We will help you deliver your story to your target audiences through multiple, impactful communications channels that build value for your company. 



Our team has a unique insight that has been gained from holding leadership positions in pharmaceutical business development and commercial strategy, investment firms and communications consultancies. This enables us to brings a well informed perspective to our communications strategy and provide valuable and trusted counsel that fosters long-term client relationships.

Katja Stout, MBiochem (Oxon), MBA
Managing Director

Katja is a communications strategist and entrepreneur with over twenty years of international experience in the life sciences and pharmaceutical industry. A serial entrepreneur, she has founded two communications consultancies.

As Managing Director and Founder of Scius Communications, Katja supported Immunocore’s $320 million financing, Europe’s largest ever private round in life sciences. Katja has also supported BC Platforms in its communications strategy and media outreach for over three years. As Co-Founder and a Board Director of Northbank communications, a leading global specialist life sciences communications firms, Katja supported the company’s growth to over 35 staff and 100 clients prior to its successful sale to College Hill (now Instinctif).

Subsequently Katja spent four years at AstraZeneca firstly as Director of Partnering Communications in the business development team and supported AZ’s notable rise in the industry league tables from number 12 to number 3 as the ‘partner of choice’. She later became Vice President of Corporate Affairs, Global Product and Portfolio Strategy (GPPS) and was a member of the GPPS leadership team. In this role she was responsible for leading the communications for all of AstraZeneca’s global product brands and launching the new GPPS function internally.

Prior to founding Northbank, Katja held in-house roles at leading investment firms including SV Life Sciences, International BioTechnology Trust and Merlin Biosciences. She also worked at life sciences investor relations firm, Russell-Welsh (now GCI Healthcare), based in San Francisco, California. Earlier in her career, Katja was Head of `communications and IR at Genset SA (now part of Merck Serono), a pioneer in personalised healthcare, listed on Nasdaq and the Nouveau Marche and based in Paris.

Katja has a Masters degree in Biochemistry from Oxford University and an MBA from Imperial College London.

Fiona Brown BA, MCIPR, MCIM
Senior Consultant

Fiona is a corporate communications specialist with 30 years experience in life sciences. She ran her own agency in the 1980s

working for the pharmaceutical, dental and animal health divisions of ICI and subsequently acted for 10 years as PR consultant to the Rothschild fund, Biotechnology Investments Limited.

Fiona has provided commercial and investor relations consultancy to a broad spectrum of companies including Shire Pharmaceuticals, IGEN Europe, Atugen AG, McCormick UK , Physiomics plc, Biovector Therapeutics SA, Healthcare Ventures Limited, 1st European Conference on Bone Morphogenic Proteins, Investing in Biotechnology Conference, London Regenerative Medicine Network and

Fiona has a BA in English, History and Philosophy from London University, and further training in marketing (CAM) and molecular biology (Birkbeck). A particular strength lies in interpreting science for a lay audience and translating this into informative copy across the various platforms available to today’s marketer.